Business Context and Reporting Period
This Form 8-K is a current report filed by Aziyo Biologics, Inc. (trading symbol: AZYO) on October 25, 2021. The filing discloses preliminary financial results for the third quarter ended September 30, 2021. The company is incorporated in Delaware and lists its Class A Common Stock on The Nasdaq Global Market.
Key Financial Metrics
The filing provides preliminary revenue figures but does not contain data regarding profit, cash flow, margins, debt, or liquidity.
- Preliminary Q3 2021 Revenue: Approximately $11.5 million.
- Prior Period Q3 2020 Revenue: $11.8 million.
- Other Metrics: The filing text does not provide clear values for net income, operating cash flow, gross margins, total debt, or cash on hand.
Material Changes
Comparing the preliminary third quarter of 2021 to the same period in 2020, revenue decreased by approximately $0.3 million (from $11.8 million to $11.5 million). The filing explicitly states that these preliminary estimates are not comprehensive and may vary from final results once the quarterly close process is complete.
Guidance, Outlook, and Risks
Outlook and Timing: Aziyo expects to issue full financial results for the third quarter of 2021 on Tuesday, November 9, 2021, followed by a conference call at 1:30 PM Pacific Time. A webcast will be available on the company's investor relations website.
Risks and Uncertainties: Management cautions that preliminary estimates are not indicative of future results. The final financial statements may differ due to the ongoing close process, additional developments, and adjustments. The company notes that estimates are subject to risks and uncertainties, many of which are outside its control and cannot be predicted.
Investor Verification Checklist
- Verify the final audited revenue figure for Q3 2021 when released on November 9, 2021, as the current $11.5 million is preliminary.
- Review the full Q3 2021 financial statements for data on profitability, cash flow, and liquidity, which are absent in this 8-K.
- Confirm whether the slight revenue decline is attributed to specific operational factors or accounting adjustments in the upcoming earnings release.
- Check the company's cash position and burn rate in the full report to assess runway, as this 8-K does not disclose liquidity metrics.